calanolide A

calanolide A

A compound derived from a Malaysian tree (Calophyllum lanigerum) that is a natural and unique non-nucleoside reverse transcriptase inhibitor (NNRTI), which appears to have two RTI-binding sites. It was believed to be active against AZT-resistant HIV-1.
References in periodicals archive ?
March 4 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals has completed a 48-subject clinical trial of Calanolide A in combination therapy for HIV.
Sarawak MediChem Pharmaceuticals will next initiate a clinical study to evaluate the Calanolide A combination therapy in HIV-infected individuals.
The lead compound, Calanolide A, is a potent non-nucleotide reverse transcriptase inhibitor anti-HIV agent, and has demonstrated pre-clinical and clinical activity against HIV.
In addition, Calanolide A has demonstrated in vitro activity against Mycobacterium tuberculosis, distinguishing it as the only anti-HIV agent with dual activity against HIV and tuberculosis, the world's number one killer among infectious diseases and the most common infection in HIV patients.
The lead compound, Calanolide A, is a potent non-nucleotide reverse transcriptase inhibitor (NNRTI) anti-HIV agent, and has demonstrated pre-clinical and clinical activity against HIV.
In addition, Calanolide A has demonstrated in vitro activity against Mycobacterium tuberculosis (TB), distinguishing it as the only anti-HIV agent with dual activity against HIV and TB, the world's number one killer among infectious diseases and the most common infection in HIV patients.
announced today that it has begun screening volunteers for a 48 subject, clinical trial of Calanolide A in combination therapy for HIV.
Calanolide A is a unique non-nucleoside reverse transcriptase inhibitor (NNRTI), which has demonstrated pre-clinical and clinical activity against HIV, and offers a favorable resistance profile to combat mutations commonly associated with the use of current HIV therapies.
Sarawak MediChem Pharmaceuticals' lead product is Calanolide A, which is a proprietary anti-HIV drug in Phase I/II clinical trials.
It holds a patent for the total synthesis of (+)- Calanolide A.
Calanolide A is the only naturally occurring anti-HIV compound known to be at an advanced stage of testing; no anti-HIV drug on the market is a natural product.
will soon begin clinical trials of Calanolide A, pending FDA approval, and will be on a fast-track schedule.